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     BSTRACT
Urinary incontinence, an uncontrolled urine leakage during the storage phase of micturition, 
is a common condition in female dogs. In intact bitches, the reported prevalence is only 0.2-0.3%, 
but in spayed bitches it varies between 3.1-20.1%. Most commonly, dogs with acquired urinary 
incontinence suffer from urethral sphincter mechanism incompetence. This condition seems to 
be multifactorial, and although the exact pathophysiology remains unclear, potential risk factors 
include gender, gonadectomy, breed, body weight, urethral length and bladder neck position. In 
daily practice, the diagnosis of urethral sphincter mechanism incompetence is usually made af-
ter eliminating other potential causes of urinary incontinence. Incontinent bitches are primarily 
treated with medications, such as alpha-adrenergic drugs, e.g. phenylpropanolamine and oestro-
gens. Surgery is recommended when patients become refractory to medical treatment. 
SAMENVATTING
Urinaire incontinentie, het ongecontroleerd verlies van urine tijdens de vullingsfase van het uri-
neren, is een veelvoorkomende aandoening bij vrouwelijke honden. De gerapporteerde prevalentie 
bij intacte teven is slechts 0,2-0,3%, maar dit varieert tussen de 3,1-20,1% bij gesteriliseerde teven. 
Honden met verworven urine-incontinentie lijden meestal aan urethrale sfinctermechanisme-incom-
petentie. Deze aandoening lijkt door meerdere factoren veroorzaakt te worden en, alhoewel de exacte 
pathofysiologie niet volledig bekend is, zijn potentiële risicofactoren geslacht, gonadectomie, ras, li-
chaamsgewicht, urethrale lengte en positie van de blaashals. In de praktijk is de diagnose van urethrale 
sfinctermechanisme-incompetentie doorgaans gebaseerd op uitsluiting van andere potentiële oorzaken 
van urine-incontinentie. Incontinente teven worden hoofdzakelijk medicamenteus behandeld met onder 
andere alfa-adrenerge geneesmiddelen, bijvoorbeeld fenylpropanolamine en oestrogenen. Chirurgie is 
aangeraden als de patiënt refractair wordt ten opzichte van de medicamenteuze behandeling.
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INTRODUCTION
Normal micturition in dogs is composed of a com-
plex interaction between the storage of urine in the 
bladder and emptying of the bladder (Fischer and 
Lane, 2011; Byron, 2015). Urinary incontinence (UI) 
is defined as an uncontrolled leakage during the stor-
age phase (Abrams et al., 2003). This can be catego-
rized in two main groups: neurogenic or non-neuro-
genic induced UI, of which, in dogs, the latter can ei-
ther occur congenitally or acquired (Applegate et al., 
2018) (Table 1). 
The prevalence of UI in intact bitches is as low as 
0.2-0.3% (Holt and Thrusfield, 1993). In spayed bitch-
es, this prevalence has historically been reported up to 
20.1% (Arnold et al., 1989), but in more recent studies 
by Forsee et al. (2013) and O’Neill et al. (2017), num-
bers closer to 3-5% have been reported. 
In this review, the most common cause of UI, the 
diagnostic procedure and medical treatment options 
are highlighted. 
ANATOMY
The lower urinary tract consists of the bladder, 
comprised of an apex, body and bladder neck, and 
the urethra, containing the external urethral sphinc-
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ter (Fischer and Lane, 2011). The external urethral 
sphincter could also be described as part of the 
sphincter mechanism and not as a separate structure. 
Micturition is coordinated through sympathetic, para-
sympathetic and somatic innervation, combined with 
actions regulated from central control centers (DiBar-
tola and Westropp, 2014) (Figure 1). The sympathetic 
hypogastric nerve, originating from spinal segment 
L1-L4, is mainly important during the storage phase 
because norepinephrine release during nerve stimula-
tion results in detrusor relaxation, filling of the urinary 
bladder and prevention of subsequent urinary leakage 
(Fischer and Lane, 2011; DiBartola and Westropp, 
2014; Byron, 2015). This is accomplished through 
activation of beta-receptors in the bladder and alpha-
1-adrenergic receptors in the smooth muscle within 
the urethral sphincter mechanism (DiBartola and 
Westropp, 2014). The pelvic nerve, which originates 
from spinal segment S1-S3, supplies parasympathetic 
innervation (Fischer and Lane, 2011). It ensures ex-
citatory input to the bladder (bladder contraction) and 
inhibitory input to the urethra (urethral relaxation), re-
sulting in urination (DiBartola and Westropp, 2014). 
Lastly, the pudendal nerve also originates from spi-
nal segment S1-S3, supplies somatic innervation and 
stimulates the external urethral sphincter (Fischer and 
Lane, 2011; DiBartola and Westropp, 2014). 
URETHRAL SPHINCTER MECHANISM IN-
COMPETENCE
Dogs with acquired UI most commonly suffer 
from urethral sphincter mechanism incompetence 
(USMI) (Byron et al., 2017). The pathophysiology of 
USMI remains incompletely elucidated. Most likely, 
this condition is multifactorial, resulting from hor-
monal, as well as structural and functional changes 
(Applegate et al., 2018). Several risk factors have 
been described for the development of USMI. 
Gender
 
 USMI can develop in both male and female 
dogs, but the condition is rare in males with a reported 
risk of up to 1% (Holt, 1990; Reichler and Hubler, 
Figure 1. Simplified representation of the innervation of the lower urinary tract. Adapted from: DiBartola and 
Westropp (2014).
Table 1. Main differential diagnoses of urinary incontinence. Adapted from: Fischer and Lane (2017).
Urinary incontinence
Neurogenic Non-neurogenic
• Lower motor neuron disorders • Urethral sphincter mechanism incompetence (USMI)
• Upper motor neuron disorders • Congenital disorders
• Detrusor urethral dyssynergia • Detrusor hyperreflexia
• Dysautonomia • Anatomical or functional urethral obstruction
   leading to secondary bladder atony
• Primary bladder atony • Bladder atony due to muscle weakness or medications
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2014). Extensive studies have been conducted in 
bitches to support the prevalence, which is not the 
case in males (Aaron et al., 1996; Forsee et al., 2013).
Gonadectomy
Spaying in dogs increases the risk of USMI (Holt 
and Thrusfield, 1993; Thrusfield et al., 1998; Reichler 
and Hubler, 2014). According to Holt (1985), approx-
imately 90% of dogs with USMI have a history of 
prior gonadectomy. In about 75% of the bitches, the 
onset of UI occurs within three years after gonadec-
tomy, but it is not uncommon that clinical signs occur 
directly after the surgery or as late as ten years after 
(Arnold et al., 1989; Reichler and Hubler, 2014).
So far, no consensus has been reached about the 
link between the age of the dog at spaying and the 
concurrent risk of USMI (Arnold et al., 1989; Arnold, 
1997; Thrusfield et al., 1998; Stöcklin-Gautschi et al., 
2001; de Bleser et al., 2011; Beauvais et al., 2012; 
Forsee et al., 2013; Reichler and Hubler, 2014). In 
earlier studies, an increased risk of developing incon-
tinence has been mentioned when spaying was per-
formed before three months of age (Thrusfield et al., 
1998; Stöcklin-Gautschi et al., 2001), or when dogs 
have had their first oestrus (Arnold et al., 1989). On 
the other hand, in more recent publications, no evi-
dence to support a relationship between age at which 
gonadectomy is performed and the development of 
USMI in bitches has been found (de Bleser et al., 
2011; Beauvais et al., 2012; Forsee et al., 2013).
The suggestion has been made that the severity of 
UI might be different depending on the age the animal 
was spayed (Reichler and Hubler, 2014). In a study by 
Arnold (1997), it was shown that gonadectomy before 
puberty resulted in UI after an increased abdominal 
pressure, as expected, but also during walks or when 
the animal was awake. Dogs neutered after puberty 
are mainly dribbling when recumbent with less inten-
sity (Stöcklin-Gautschi et al., 2001). 
Recently, Byron et al. (2017) described a relation-
ship between gonadectomy and body weight, which 
will be discussed below.
The extent of surgery, ovariectomy versus ovario-
hysterectomy, does not result in different continence 
rates (Van Goethem et al., 2006). Likewise, the inci-
dence of USMI is not different in dogs with elective 
versus emergency procedure (Forsee et al., 2013). 
Breed and body weight
Urinary incontinence is more common in medium 
to large-breed dogs (de Bleser et al., 2011). Previous 
studies have demonstrated that dogs weighing more 
than 10 kg have a 3.7-times higher risk of developing 
USMI than smaller dogs (de Bleser et al., 2011), and 
dogs weighing more than 15 kg have a 7.2-times high-
er risk (Forsee et al., 2013). Additionally, Byron et al. 
(2017) found a relationship between age at the time 
of ovariohysterectomy and body weight in developing 
USMI. According to this study, the risk of developing 
USMI for dogs with an expected adult weight of more 
than 25 kg decreases for every month gonadectomy 
is postponed during their first year. In the same study, 
dogs weighing less than 15 kg were reported not to be 
susceptible to this risk, making it reasonable to spay 
these dogs prior to the first heat to reduce the risk of 
unwanted pregnancy or developing mammary neopla-
sia and pyometra (Byron et al., 2017). Some breeds 
are clearly overrepresented in the literature and have 
an increased risk of USMI, such as Doberman pin-
scher, Old English sheepdog, Springer spaniel, boxer, 
rottweiler, Weimaraner, Giant schnauzer and Irish set-
ter (White, 2001; Reichler and Hubler, 2014). Based 
on an investigation in 928 entire or neutered male and 
female Dobermans, a prevalence of 15.8% was found 
(Mandigers et al., 2006). Nevertheless, developing 
USMI is not restricted to these breeds; all breeds can 
be affected. 
Urethral length and bladder neck position
Holt (1985c) documented that incontinent bitches 
are more likely to present with intrapelvic bladder 
neck than continent bitches that usually have intra-
abdominal bladder neck (Holt, 1985b). Radiographi-
cally, spayed bitches also tend to have a shorter ure-
thra than intact bitches, although it is unknown how 
decisive these radiographic findings are in the occur-
rence of UI (Holt, 1985c; Wang et al., 2006).
DIAGNOSIS
Diagnosing USMI may be challenging and typi-
cally relies on elimination of other potential causes 
of UI (Applegate et al., 2018) (Table 1). Congenital 
conditions, e.g. ectopic ureter and patent urachus, 
must be evaluated in case an animal is incontinent 
since birth or at least before spaying (Byron, 2015). 
Affected dogs may present with either intermittent or 
continuous UI (Holt, 1985c), and observing micturi-
tion increases the chance of correct diagnosis (By-
ron, 2015). It is important to monitor for conscious 
or unconscious urination, stranguria and to palpate 
the bladder afterwards for residual volume (Byron, 
2015). Findings on general physical examination are 
unfortunately not specific for the presence of USMI 
(Applegate et al., 2018). Neurological examination 
is indicated with particular interest for the urogeni-
tal system to evaluate the perineal reflex (pudendal 
nerve), as well as a vaginal and rectal examination to 
diagnose anatomical abnormalities (Labato, 2018). 
Additional diagnostic procedures are necessary to 
diagnose USMI (Applegate et al., 2018). The ideal 
diagnostic work-up to support the presumptive diag-
nosis of USMI includes a complete blood count, bio-
chemistry panel, urinalysis (including urine specific 
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gravity and urine culture), abdominal radiographs and 
abdominal ultrasound. Although most of these diag-
nostics are within normal limits when USMI is present 
in a dog, these tests should be performed to rule out 
concurrent diseases (Applegate et al., 2018). Perform-
ing abdominal radiographs and/or ultrasound allows 
excluding the presence of urinary calculi and neopla-
sia including possible metastatic disease. Urodynamic 
studies should be performed to make the definitive 
diagnosis of USMI (Applegate et al., 2018). When 
a minimum database is obtained but the specialized 
equipment for urodynamic studies is not available, it 
is acceptable to start empirical treatment and confirm 
the diagnosis of USMI as a result of treatment success 
(Applegate et al., 2018). However, diagnostics should 
be repeated in case of a recurrence of UI (Reichler and 
Hubler, 2014).
MEDICAL TREATMENT
Medical management is always the first treatment 
option because it is not invasive and successful in 
up to 97% of cases (Applegate et al., 2018). Alpha-
adrenergic drugs are the preferred initial treatment in 
dogs with USMI (Richter and Ling, 1985; Applegate 
et al., 2018). It is important to know the potential side 
effects and contraindications of the medications de-
scribed below to decide on the best choice of drugs 
and alter treatment accordingly. 
Alpha-adrenergic drugs
Phenylpropanolamine, a sympathomimetic alpha-
adrenergic drug, increases urethral sphincter tone 
by tensioning smooth muscles in both the bladder 
neck and urethra (Richter and Ling, 1985; Scott et 
al., 2002; Applegate et al., 2018). The reported effi-
cacy of this drug varies between 86-97% (Scott et al., 
2002; Claeys et al., 2011). One mg/kg body weight 
is administered two to three times a day (Scott et 
al., 2002), or alternatively 1.5 mg/kg body weight 
can be administered once daily (Claeys et al., 2011). 
Improvement should be noticed within three to four 
weeks after starting treatment (Applegate et al., 2018). 
Side effects of phenylpropanolamine include anxiety, 
excitement and aggression, which may result in an 
increased sympathetic tone (Burgherr et al., 2007). 
Other alpha-adrenergic drugs, such as ephedrine or 
pseudoephedrine, illustrate more adverse effects, e.g. 
panting, hyporexia and lethargy, result in lower ure-
thral closure pressure and have a lower efficacy of 25-
75% only (Byron et al., 2007; Applegate et al., 2018). 
Phenylpropanolamine or other alpha-adrenergic drugs 
are contraindicated when hypertension could have di-
sastrous consequences, e.g. in heart and kidney dis-
ease or glaucoma (Burgherr et al., 2007).
The effect of alpha-adrenergic drugs decreases 
over time (Richter and Ling, 1985; White and Pome-
roy, 1989; Reichler and Hubler, 2014). Unfortunately, 
there is no cut-off period available from previously 
published studies as to when to expect decreased ef-
fect of medications or refractory incontinence. 
Oestrogens
Estriol, a short-acting oestrogen, increases urethral 
closure pressure by stimulating urethral mucosal tis-
sue (Mandigers and Nell, 2001). The reported efficacy 
is 65–83% (Arnold, 1997; Mandigers and Nell, 2001). 
A dose of 2 mg, irrespective of the dog’s bodyweight, 
is administered orally once daily for the first seven 
to fourteen days (Byron, 2018). Clinical improvement 
may be expected within this time frame (Mandigers 
and Nell, 2001). The recommended dose is reduced 
after improvement by 0.5 mg per week until the mini-
mum effective dose is reached, which can be con-
tinued every other day (Mandigers and Nell, 2001; 
Fischer and Lane, 2017). If no response to treatment 
is achieved after the first two weeks, it may be bene-
ficial to continue dosing 2 mg/dog until clinical im-
provement is appreciated (Mandigers and Nell, 2001). 
Potential adverse effects include vulvar hyperplasia, 
vaginal discharge, attractiveness to males and pyome-
tra in entire and ovariectomized bitches (Byron et al., 
2007; Schotanus et al., 2008; Applegate et al., 2018). 
Alternatively, diethylstilbestrol can be administered, 
which is a long-acting oestrogen. However, this could 
induce more adverse effects than estriol, such as mye-
losuppression (Hoeijmakers et al., 2003; Sontas et al., 
2009).
Multidrug therapy
When monotherapy does not provide satisfactory 
results, multidrug therapy may be initiated (Aaron et 
al., 1996; Reichler et al., 2003). For example, com-
bining alpha-adrenergic drugs with oestrogens would 
theoretically result in a synergistic effect because 
of their different mechanism of action (Aaron et al., 
1996; Applegate et al., 2018). No recommendations 
have been published regarding altered dosing sched-
ules or the consequences of this drug combination 
protocol on potential side effects. Hamaide et al. 
(2006) used the doses described above for phenylpro-
panolamine and estriol to investigate urodynamic and 
morphologic changes, but multidrug therapy did not 
appear beneficial compared to monotherapy.
Reichler et al. (2003) described a combination 
therapy of gonadotropin-releasing hormone (GnRH) 
analogues and phenylpropanolamine 1.5 mg/kg three 
times a day in dogs. Leuprolide, deslorelin and buse-
relin, examples of GnRH analogues, are injected 
subcutaneously and result in a suppression of follicle 
stimulating hormone and luteinizing hormone. The 
doses used include 11.25 mg, 5-10 mg, and 6.3 mg, re-
spectively. These formulations are effective between 
one to six months (Reichler et al., 2003). Although 
the consequences to the urethral sphincter tone are in-
completely elucidated, these GnRH analogues seem 
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to have temporary positive effects in almost 50% of 
dogs with USMI (Reichler et al., 2003, 2006). Long-
term results of GnRH solo treatment are disappoint-
ing, with only a few dogs still continent after a mean 
of 247 days even after repeated injections. So far, no 
side effects of this treatment have been mentioned 
(Reichler et al., 2003). 
Refractory patients
Refractory patients are dogs that do not respond 
or tolerate medical treatment, or initially respond to 
medications and ultimately show clinical symptoms 
suggestive for USMI. It has been reported that up to 
56% of dogs develop refractory incontinence (Currao 
et al., 2013). Treatment options for these patients in-
clude surgical treatment, such as urethral bulking, col-
posuspension, urethropexy and an artificial urethral 
sphincter (Applegate et al., 2018). 
CONCLUSION
Approximately 3-5% of spayed bitches are affect-
ed with UI. USMI is the most common cause of ac-
quired UI in spayed bitches and the frequency is influ-
enced by gender, breed, body weight, gonadectomy, 
urethral length and bladder neck position. Diagnosing 
USMI is usually based on excluding other causes of 
incontinence and can be confirmed after performing 
urodynamic studies. USMI is primarily treated with 
medications, such as phenylpropanolamine and es-
triol, of which the former is the treatment of choice. 
Additional scientific research and a longer follow-up 
period are required to further investigate what causes 
refractory incontinence, the benefits of multidrug 
therapy including the dosing schedules required in 
practice, and when refractory incontinence is likely to 
occur. Surgery is recommended when bitches become 
refractory to medical treatment of UI. 
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